Travere Therapeutics Inc (NAS:TVTX)
$ 6.16 -0.18 (-2.84%) Market Cap: 468.95 Mil Enterprise Value: 431.93 Mil PE Ratio: 0 PB Ratio: 6.33 GF Score: 54/100

Retrophin Inc at Barclays Global Healthcare Conference Transcript

Mar 11, 2020 / 01:00PM GMT
Release Date Price: $14.79 (-2.83%)
Gena Wang
Barclays Bank PLC, Research Division - Research Analyst

Thank you, everyone. My name is Gena Wang. I'm SMID-cap biotech analyst at the Barclays. I first hope everyone stay healthy, and I would like to thank all the participants, investors, companies, especially our event team and corporate access team, who made this virtual health care conference possible.

With that, I would like to introduce our next speakers from Retrophin. We have Eric Dube, Chief Executive Officer; we also have Chris Cline, SVP of Investor Relations.

Eric, I will hand over to you.

Eric M. Dube
Retrophin, Inc. - President, CEO & Director

Okay. Thank you, Gena, and thank you, Barclays, for the opportunity to present some updates on our company.

Let me go to Slide 2. Today, I will be speaking to a number of forward-looking statements, and you can see our disclosures here, online and in our SEC filings.

If you move to Slide 3, I'd like to give a brief overview of our company. At Retrophin, we are completely dedicated to developing and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot